1. Discovery of a Selective Allosteric Inhibitor Targeting Macrodomain 2 of Polyadenosine-Diphosphate-Ribose Polymerase 14
- Author
-
Franz Bracher, Christian Sieg, Marion Schuller, Ivan Ahel, Ian Gibbs-Seymour, Jonathan M. Elkins, Kerstin Riedel, Benedikt M. Kessler, Kristin Uth, Stefan Knapp, and André P. Gehring
- Subjects
0301 basic medicine ,Poly ADP ribose polymerase ,Protein domain ,Allosteric regulation ,Biology ,Poly(ADP-ribose) Polymerase Inhibitors ,Biochemistry ,Poly (ADP-Ribose) Polymerase Inhibitor ,Article ,Cell Line ,Small Molecule Libraries ,03 medical and health sciences ,chemistry.chemical_compound ,Allosteric Regulation ,Protein Domains ,Humans ,Adenosine Diphosphate Ribose ,Adenosine diphosphate ribose ,General Medicine ,Small molecule ,3. Good health ,Molecular Docking Simulation ,030104 developmental biology ,chemistry ,Molecular Medicine ,Poly(ADP-ribose) Polymerases ,Sequence motif ,DNA Damage - Abstract
Macrodomains are conserved protein interaction modules that can be found in all domains of life as well as in certain viruses. Macrodomains mediate recognition of sequence motifs harbouring adenosine diphosphate ribose (ADPR) modifications, thereby regulating a variety of cellular processes. Due to their role in cancer or viral pathogenesis, macrodomains have emerged as potential therapeutic targets, but the unavailability of small molecule inhibitors has hampered target validation studies so far. Here, we describe an efficient screening strategy for identification of small molecule inhibitors that displace ADPR from macrodomains. We report the discovery and characterisation of a macrodomain inhibitor, GeA-69, selectively targeting macrodomain 2 (MD2) of PARP14 with low micromolar affinity. Co-crystallisation of a GeA-69 analogue with PARP14 MD2 revealed an allosteric binding mechanism explaining its selectivity over other human macrodomains. We show that GeA-69 engages PARP14 MD2 in intact cells and prevents its localisation to sites of DNA damage.
- Published
- 2017